文献速递帕金森病与运动障碍认知障碍与痴呆

18F-PI-2620作为进行性核上性麻痹生物标志物的评估

Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.
PubMed 文献 · JAMA Neurol · 2020-01-01

这项多中心横断面研究评估了新型tau示踪剂18F-PI-2620在临床诊断的进行性核上性麻痹(PSP)患者中的价值,并与健康对照和疾病对照比较。尸检放射自显影显示PSP患者有可阻断的示踪剂结合。体内PET显示PSP靶区结合显著升高,鉴别PSP-RS与任何对照的敏感性和特异性分别为85%和77%。

要点

  • 18F-PI-2620 PET在PSP患者靶区结合显著升高。
  • 鉴别PSP-RS与对照的敏感性85%、特异性77%。
  • 该示踪剂有望辅助PSP的可靠诊断。

核心结论

  • 多中心评估表明18F-PI-2620有助于鉴别疑似PSP患者,可能促进更可靠的PSP诊断。

研究设计与样本

  • 横断面研究,纳入60例PSP患者(40例PSP-RS,20例PSP-non-RS)、10例健康对照和20例疾病对照,在5个中心进行动态18F-PI-2620 PET(注射后0至60分钟)。
  • 另对独立的PSP-RS和健康对照样本进行尸检放射自显影。

主要发现

  • 尸检放射自显影显示PSP患者有可阻断的18F-PI-2620结合,健康对照无结合。
  • PSP vs对照组在苍白球内侧差异最强(平均[SD]分布容积比:PSP-RS 1.21[0.10];PSP-non-RS 1.12[0.11];健康对照1.00[0.08];帕金森病/多系统萎缩1.03[0.05];阿尔茨海默病1.08[0.06])。
  • 使用至少1个阳性靶区分类时,检测PSP-RS vs任何对照组的敏感性和特异性分别为85%和77%。

关键数值与推荐

  • PSP-RS患者40例(66.7%),平均[SD]年龄71[6]岁,平均[SD]PSP评定量表评分38[15](范围13-71)。
  • PSP-non-RS患者20例(33.3%),平均[SD]年龄71[9]岁,平均[SD]PSP评定量表评分24[11](范围11-41)。
  • 健康对照10例,平均[SD]年龄67[7]岁;疾病对照20例(帕金森病和多系统萎缩10例,阿尔茨海默病10例)。

临床怎么用

  • 18F-PI-2620 PET可作为辅助生物标志物,用于疑似PSP患者的鉴别诊断。

局限性

  • 4例PSP-RS和2例PSP-non-RS因动态PET扫描不完整被排除。
  • 样本量有限,且为横断面设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against tau in PSP would strongly benefit from biomarkers that support diagnosis. OBJECTIVE: To investigate the potential of the novel tau radiotracer 18F-PI-2620 as a biomarker in patients with clinically diagnosed PSP. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study, participants underwent dynamic 18F-PI-2620 positron emission tomography (PET) from 0 to 60 minutes after injection at 5 different centers (3 in Germany, 1 in the US, and 1 in Australia). Patients with PSP (including those with Richardson syndrome [RS]) according to Movement Disorder Society PSP criteria were examined together with healthy controls and controls with disease. Four additionally referred individuals with PSP-RS and 2 with PSP-non-RS were excluded from final data analysis owing to incomplete dynamic PET scans. Data were collected from December 2016 to October 2019 and were analyzed from December 2018 to December 2019. MAIN OUTCOMES AND MEASURES: Postmortem autoradiography was performed in independent PSP-RS and healthy control samples. By in vivo PET imaging, 18F-PI-2620 distribution volume ratios were obtained in globus pallidus internus and externus, putamen, subthalamic nucleus, substantia nigra, dorsal midbrain, dentate nucleus, dorsolateral, and medial prefrontal cortex. PET data were compared between patients with PSP and control groups and were corrected for center, age, and sex. RESULTS: Of 60 patients with PSP, 40 (66.7%) had RS (22 men [55.0%]; mean [SD] age, 71 [6] years; mean [SD] PSP rating scale score, 38 [15]; score range, 13-71) and 20 (33.3%) had PSP-non-RS (11 men [55.0%]; mean [SD] age, 71 [9] years; mean [SD] PSP rating scale score, 24 [11]; score range, 11-41). Ten healthy controls (2 men; mean [SD] age, 67 [7] years) and 20 controls with disease (of 10 [50.0%] with Parkinson disease and multiple system atrophy, 7 were men; mean [SD] age, 61 [8] years; of 10 [50.0%] with Alzheimer disease, 5 were men; mean [SD] age, 69 [10] years). Postmortem autoradiography showed blockable 18F-PI-2620 binding in patients with PSP and no binding in healthy controls. The in vivo findings from the first large-scale observational study in PSP with 18F-PI-2620 indicated significant elevation of tracer binding in PSP target regions with strongest differences in PSP vs control groups in the globus pallidus internus (mean [SD] distribution volume ratios: PSP-RS, 1.21 [0.10]; PSP-non-RS, 1.12 [0.11]; healthy controls, 1.00 [0.08]; Parkinson disease/multiple system atrophy, 1.03 [0.05]; Alzheimer disease, 1.08 [0.06]). Sensitivity and specificity for detection of PSP-RS vs any control group were 85% and 77%, respectively, when using classification by at least 1 positive target region. CONCLUSIONS AND RELEVANCE: This multicenter evaluation indicates a value of 18F-PI-2620 to differentiate suspected patients with PSP, potentially facilitating more reliable diagnosis of PSP.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Brendel M, Barthel H, van Eimeren T, et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020. PMID: 33165511. doi:10.1001/jamaneurol.2020.2526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。